Details:
Akynzeo is a combination of netupitant, a selective antagonist of human substance P/neurokinin 1 (NK-1) receptors and palonosetron, a 5-HT3 receptor antagonist with a strong binding affinity for this receptor. It is indicated for nausea due to cancer chemotherapy.
Lead Product(s): Netupitant,Palonosetron
Therapeutic Area: Gastroenterology Product Name: Akynzeo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2023
Details:
Akynzeo (netupitant) is a 5-HT3 and NK1 receptor antagonist fixed combination approved in Europe in adults for the prevention of acute and delayed nausea and vomiting associated with cisplatin-based highly emetogenic chemotherapy and moderately emetogenic chemotherapy.
Lead Product(s): Netupitant,Palonosetron
Therapeutic Area: Gastroenterology Product Name: Akynzeo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Immedica Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 24, 2023
Details:
AKYNZEO (Netupitant) is the first and only 5-HT3 and NK1 receptor antagonist fixed combination approved in adults for the prevention of acute and delayed nausea and vomiting associated with cisplatin based highly emetogenic chemotherapy and moderately emetogenic chemotherapy.
Lead Product(s): Netupitant,Palonosetron
Therapeutic Area: Gastroenterology Product Name: Akynzeo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
Akynzeo is the first and only 5-HT3 and NK1 receptor antagonist fixed combination approved in adults for the prevention of acute and delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy.
Lead Product(s): Netupitant,Palonosetron
Therapeutic Area: Gastroenterology Product Name: Akynzeo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
Under the terms of the agreement, Farma Mondo will manage the commercialization of AKYNZEO® in Estonia and Latvia. AKYNZEO® hard capsules (combination of netupitant/palonosetron), for the treatment of chemotherapy-induced nausea and vomiting (CINV) in adults.
Lead Product(s): Netupitant,Palonosetron
Therapeutic Area: Gastroenterology Product Name: Akynzeo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Helsinn Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 28, 2022
Details:
Sandoz has shipped pantoprazole sodium for injection, 40 mg to Civica Rx to supply the hospitals it serves as part of a multiyear collaboration to help reduce supply shortages, with several other medicines on the way before the end of the year.
Lead Product(s): Pantoprazole Sodium
Therapeutic Area: Gastroenterology Product Name: Pantoprazole Sodium-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Civica Rx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 02, 2020
Details:
Based on Phase 3 trial data, Rizmoic has been shown to increase the frequency of bowel movements compared to placebo in patients either with cancer or chronic non-cancer pain who had previously received laxative treatment.
Lead Product(s): Naldemedine Tosylate
Therapeutic Area: Gastroenterology Product Name: Rizmoic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Shionogi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2020
Details:
Ferring joins with UCB to promote CIMZIA prefilled syringe for Crohn’s disease in the United States. Co-promotion strengthens commitment to patients living with Crohn’s disease by reaching more gastroenterologists while also continuing patient support programs.
Lead Product(s): Certolizumab Pegol
Therapeutic Area: Gastroenterology Product Name: Cimzia
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: UCB Pharma S.A
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 08, 2020